substituted 3 - chloro - 2 - hydrazonomethyl - 4 - aza - 2.4 - pentadiennitrile, methods for their preparation and medicines containing them

摘要

1427849 3 - Chloro - 2 - hydrazonomethyl- 4 - aza - 2,4 - pentadienenitriles BYK GULDEN LOMBERG CHEMISCHE FABRIK GmbH 5 Sept 1973 [8 Sept 1972 (3)] 41666/73 Heading C2C Novel compounds I in which RSP1/SP and RSP2/SP are a C 1-7 alkyl, C 2-7 alkenyl or C 2-7 alkynyl group or together represent C 2-5 alkylene (in which one or more methylene groups may be replaced by O, S, or NRSP7/SP) RSP3/SP is C(=X)RSP4/SP, C(=X)-Y-RSP4/SP or [in which RSP4/SP is hydrogen, a C 1-14 alkyl, C 2-7 alkenyl or C 2-7 alkynyl group in which a methylene group may be replaced by oxygen and in which alkyl may be substituted by an NRSP5/SPRSP6/SP group, C 3-6 cycloalkyl optionally substituted by an NRSP5/SPRSP6/SP group or a phenyl or phenyl C 1-6 alkyl group (optionally substituted by C 1-4 alkyl, C 1-7 alkoxy, C 1-7 alkylthio, C 2-5 alkoxycarbonyl halogen, CF 3 , NO 2 and/or CN) RSP5/SP and RSP6/SP are hydrogen a C 1-7 alkyl, C 2-7 alkenyl or C 2-7 alkynyl group in which a methylene group may be replaced by oxygen, C 3-6 cycloalkyl or together represent C 2-5 alkylene in which one or more methylene groups may be replaced by O, S or NRSP7/SP, X is O, S or NRSP7/SP, Y is O, S or NH and RSP7/SP is hydrogen, C 1-7 alkyl C 2-7 alkenyl or C 2-7 alkynyl C 2-7 alkenyl or C 2-7 alkynyl] and their salts are prepared by reaction of a compound II RSP1/SPRSP2/SPN-CH=N-C(Cl)=C(CN)-CHO with RSP3/SP-NH-NH 2 . Compounds I prepared are those in which RSP1/SP and RSP2/SP are methyl and R 3 is (in which RSP4/SP is hydrogen, C 1-14 alkyl in which a methylene group is optionally replaced by -O-, cyclohexyl, phenyl, p-methoxyphenyl, p-cyanophenyl or benzyl), -C(=Y)-NRSP5/SPRSP6/SP (in which R 5 and R 6 are hydrogen, methyl or phenyl and Y is O, S or NH). Compounds II are prepared by hydrolysis of in which RSP8/SP and RSP9/SP are defined as for RSP1/SP and RSP2/SP and Z is an anion. Compounds I inhibit xanthineoxidase and may also be used for treating coronary insufficiency and arrhythmias. They form with a suitable vehicle a pharmaceutical composition, which may be administered orally or parenterally.